Biomerica (BMRA) Competitors

OptiNose (NASDAQ:OPTN) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.

Does the media favor OPTN or BMRA?

In the previous week, OptiNose and OptiNose both had 1 articles in the media. OptiNose's average media sentiment score of 1.94 beat Biomerica's score of 0.00 indicating that OptiNose is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptiNose	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biomerica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings & valuation, OPTN or BMRA?

Biomerica has lower revenue, but higher earnings than OptiNose. Biomerica is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptiNose	$70.99M	0.82	-$35.48M	-$4.20	-1.37
Biomerica	$5.41M	2.83	-$5.98M	-$0.34	-2.46

Is OPTN or BMRA more profitable?

OptiNose has a net margin of -41.16% compared to Biomerica's net margin of -100.52%. OptiNose's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptiNose	-41.16%	N/A	-27.42%
Biomerica	-100.52%	-90.19%	-64.54%

Which has more risk & volatility, OPTN or BMRA?

OptiNose has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Biomerica has a beta of -0.98, indicating that its share price is 198% less volatile than the S&P 500.

Do analysts rate OPTN or BMRA?

OptiNose currently has a consensus price target of $16.67, indicating a potential upside of 188.85%. Given OptiNose's stronger consensus rating and higher possible upside, research analysts clearly believe OptiNose is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptiNose	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Biomerica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders have more ownership in OPTN or BMRA?

85.6% of OptiNose shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 2.3% of OptiNose shares are owned by insiders. Comparatively, 15.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor OPTN or BMRA?

OptiNose received 112 more outperform votes than Biomerica when rated by MarketBeat users. However, 67.82% of users gave Biomerica an outperform vote while only 63.68% of users gave OptiNose an outperform vote.

Company	Underperform	Outperform
OptiNose	Outperform Votes 249 63.68%	Underperform Votes 142 36.32%
Biomerica	Outperform Votes 137 67.82%	Underperform Votes 65 32.18%

Summary

OptiNose beats Biomerica on 12 of the 17 factors compared between the two stocks.